Survival was adequate for analysis and there was no difference in survival amongst neratinib- treated mice compared to controls. There were decreased body weights in the 20 and 50 mg/kg/day-treated males and in 125 mg/kg/day-treated females. Clinical signs included decreased activity, hunched posture, thin appearance, tremors, ungroomed fur, changes in respiration (labored, shallow, and/or increased), apparent hypothermia (cold to touch), dehydration, and/or decreased feces. Mild incidences of cellularity or inflammation were observed at 50 mg/kg in males and 125 mg/kg in females. No drug-related neoplasms were identified in this study following daily oral administration of neratinib.
Survival was adequate for analysis and there was no difference in survival amongst neratinib- treated mice compared to controls. There were decreased body weights in the 20 and 50 mg/kg/day-treated males and in 125 mg/kg/day-treated females. Clinical signs included decreased activity, hunched posture, thin appearance, tremors, ungroomed fur, changes in respiration (labored, shallow, and/or increased), apparent hypothermia (cold to touch), dehydration, and/or decreased feces. Mild incidences of cellularity or inflammation were observed at 50 mg/kg in males and 125 mg/kg in females. No drug-related neoplasms were identified in this study following daily oral administration of neratinib.
正在翻译中..